CAR-T Therapy in Haematological Malignancy Market Report

Global and Region CAR-T Therapy in Haematological Malignancy Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 30, 2022
  • PAGES：189
  • REPORT CODE：GMM915691
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of CAR-T Therapy in Haematological Malignancy market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of CAR-T Therapy in Haematological Malignancymarket, defines the market attractiveness level of CAR-T Therapy in Haematological Malignancy market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of CAR-T Therapy in Haematological Malignancy industry, describes the types of CAR-T Therapy in Haematological Malignancy market, the applications of major players and the market size, and deeply analyzes the current situation of the global CAR-T Therapy in Haematological Malignancy market and the development prospects and opportunities of CAR-T Therapy in Haematological Malignancy industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global CAR-T Therapy in Haematological Malignancy market in Chapter 13.

    By Player:

    • Pfizer

    • CARsgen Therapeutics

    • Allogene Therapeutics

    • Collectis

    • Gilead (Kite Pharma)

    • Novartis

    • Bluebird Bio

    • Autolus Therapeutics

    • Aurora BioPharma

    • Celyad

    • Celgene (Juno Therapeutics)

    • Mustang Bio

    • Sorrento Therapeutics

    By Type:

    • Allogeneic

    • Autologous

    By End-User:

    • Hospitals

    • Cancer Research Centers

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 CAR-T Therapy in Haematological Malignancy Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 CAR-T Therapy in Haematological Malignancy Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 CAR-T Therapy in Haematological Malignancy Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 CAR-T Therapy in Haematological Malignancy Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise CAR-T Therapy in Haematological Malignancy Market Analysis and Outlook to 2022

    • 7.1 Global CAR-T Therapy in Haematological Malignancy Consumption (2017-2022)

    • 7.2 United States CAR-T Therapy in Haematological Malignancy Consumption (2017-2022)

    • 7.3 Europe CAR-T Therapy in Haematological Malignancy Consumption (2017-2022)

    • 7.4 China CAR-T Therapy in Haematological Malignancy Consumption (2017-2022)

    • 7.5 Japan CAR-T Therapy in Haematological Malignancy Consumption (2017-2022)

    • 7.6 India CAR-T Therapy in Haematological Malignancy Consumption (2017-2022)

    • 7.7 South Korea CAR-T Therapy in Haematological Malignancy Consumption (2017-2022)

    8 Region and Country-wise CAR-T Therapy in Haematological Malignancy Market Analysis and Outlook to 2028

    • 8.1 Global CAR-T Therapy in Haematological Malignancy Consumption Forecast (2022-2028)

    • 8.2 United States CAR-T Therapy in Haematological Malignancy Consumption Forecast (2022-2028)

    • 8.3 Europe CAR-T Therapy in Haematological Malignancy Consumption Forecast (2022-2028)

    • 8.4 China CAR-T Therapy in Haematological Malignancy Consumption Forecast (2022-2028)

    • 8.5 Japan CAR-T Therapy in Haematological Malignancy Consumption Forecast (2022-2028)

    • 8.6 India CAR-T Therapy in Haematological Malignancy Consumption Forecast (2022-2028)

    • 8.7 South Korea CAR-T Therapy in Haematological Malignancy Consumption Forecast (2022-2028)

    9 Global CAR-T Therapy in Haematological Malignancy Market Outlook by Types and Applications to 2022

    • 9.1 Global CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Allogeneic Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Autologous Consumption and Growth Rate (2017-2022)

    • 9.2 Global CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Cancer Research Centers Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Global CAR-T Therapy in Haematological Malignancy Market Outlook by Types and Applications to 2028

    • 10.1 Global CAR-T Therapy in Haematological Malignancy Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Allogeneic Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Autologous Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global CAR-T Therapy in Haematological Malignancy Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Cancer Research Centers Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global CAR-T Therapy in Haematological Malignancy Import and Export Analysis (Top 5 Countries)

    • 11.1 Global CAR-T Therapy in Haematological Malignancy Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global CAR-T Therapy in Haematological Malignancy Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 CAR-T Therapy in Haematological Malignancy Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global CAR-T Therapy in Haematological Malignancy Market Competitive Analysis

    • 14.1 Pfizer

      • 14.1.1 Pfizer Company Details

      • 14.1.2 Pfizer CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Pfizer CAR-T Therapy in Haematological Malignancy Product and Service

    • 14.2 CARsgen Therapeutics

      • 14.2.1 CARsgen Therapeutics Company Details

      • 14.2.2 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product and Service

    • 14.3 Allogene Therapeutics

      • 14.3.1 Allogene Therapeutics Company Details

      • 14.3.2 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product and Service

    • 14.4 Collectis

      • 14.4.1 Collectis Company Details

      • 14.4.2 Collectis CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Collectis CAR-T Therapy in Haematological Malignancy Product and Service

    • 14.5 Gilead (Kite Pharma)

      • 14.5.1 Gilead (Kite Pharma) Company Details

      • 14.5.2 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product and Service

    • 14.6 Novartis

      • 14.6.1 Novartis Company Details

      • 14.6.2 Novartis CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Novartis CAR-T Therapy in Haematological Malignancy Product and Service

    • 14.7 Bluebird Bio

      • 14.7.1 Bluebird Bio Company Details

      • 14.7.2 Bluebird Bio CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Bluebird Bio CAR-T Therapy in Haematological Malignancy Product and Service

    • 14.8 Autolus Therapeutics

      • 14.8.1 Autolus Therapeutics Company Details

      • 14.8.2 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product and Service

    • 14.9 Aurora BioPharma

      • 14.9.1 Aurora BioPharma Company Details

      • 14.9.2 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product and Service

    • 14.10 Celyad

      • 14.10.1 Celyad Company Details

      • 14.10.2 Celyad CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Celyad CAR-T Therapy in Haematological Malignancy Product and Service

    • 14.11 Celgene (Juno Therapeutics)

      • 14.11.1 Celgene (Juno Therapeutics) Company Details

      • 14.11.2 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product and Service

    • 14.12 Mustang Bio

      • 14.12.1 Mustang Bio Company Details

      • 14.12.2 Mustang Bio CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Mustang Bio CAR-T Therapy in Haematological Malignancy Product and Service

    • 14.13 Sorrento Therapeutics

      • 14.13.1 Sorrento Therapeutics Company Details

      • 14.13.2 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of CAR-T Therapy in Haematological Malignancy

    • Figure CAR-T Therapy in Haematological Malignancy Picture

    • Table Global CAR-T Therapy in Haematological Malignancy Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global CAR-T Therapy in Haematological Malignancy Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global CAR-T Therapy in Haematological Malignancy Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global CAR-T Therapy in Haematological Malignancy Consumption by Country (2017-2022)

    • Figure United States CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2017-2022)

    • Table Europe CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2017-2022)

    • Figure China CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2017-2022)

    • Figure Japan CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2017-2022)

    • Figure India CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2017-2022)

    • Figure South Korea CAR-T Therapy in Haematological Malignancy Consumption and Growth Rate (2017-2022)

    • Figure Global CAR-T Therapy in Haematological Malignancy Consumption Forecast by Country (2022-2028)

    • Figure United States CAR-T Therapy in Haematological Malignancy Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe CAR-T Therapy in Haematological Malignancy Consumption Forecast and Growth Rate (2022-2028)

    • Figure China CAR-T Therapy in Haematological Malignancy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan CAR-T Therapy in Haematological Malignancy Consumption Forecast and Growth Rate (2022-2028)

    • Figure India CAR-T Therapy in Haematological Malignancy Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea CAR-T Therapy in Haematological Malignancy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Allogeneic Consumption and Growth Rate (2017-2022)

    • Figure Global Autologous Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Cancer Research Centers Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Allogeneic Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Autologous Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Cancer Research Centers Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global CAR-T Therapy in Haematological Malignancy Import by Region (Top 5 Countries) (2017-2028)

    • Table Global CAR-T Therapy in Haematological Malignancy Export by Region (Top 5 Countries) (2017-2028)

    • Table Pfizer (Foundation Year, Company Profile and etc.)

    • Table Pfizer CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer CAR-T Therapy in Haematological Malignancy Product and Service

    • Table CARsgen Therapeutics (Foundation Year, Company Profile and etc.)

    • Table CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

    • Table CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product and Service

    • Table Allogene Therapeutics (Foundation Year, Company Profile and etc.)

    • Table Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product and Service

    • Table Collectis (Foundation Year, Company Profile and etc.)

    • Table Collectis CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Collectis CAR-T Therapy in Haematological Malignancy Product and Service

    • Table Gilead (Kite Pharma) (Foundation Year, Company Profile and etc.)

    • Table Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product and Service

    • Table Novartis (Foundation Year, Company Profile and etc.)

    • Table Novartis CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis CAR-T Therapy in Haematological Malignancy Product and Service

    • Table Bluebird Bio (Foundation Year, Company Profile and etc.)

    • Table Bluebird Bio CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bluebird Bio CAR-T Therapy in Haematological Malignancy Product and Service

    • Table Autolus Therapeutics (Foundation Year, Company Profile and etc.)

    • Table Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product and Service

    • Table Aurora BioPharma (Foundation Year, Company Profile and etc.)

    • Table Aurora BioPharma CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product and Service

    • Table Celyad (Foundation Year, Company Profile and etc.)

    • Table Celyad CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celyad CAR-T Therapy in Haematological Malignancy Product and Service

    • Table Celgene (Juno Therapeutics) (Foundation Year, Company Profile and etc.)

    • Table Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product and Service

    • Table Mustang Bio (Foundation Year, Company Profile and etc.)

    • Table Mustang Bio CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mustang Bio CAR-T Therapy in Haematological Malignancy Product and Service

    • Table Sorrento Therapeutics (Foundation Year, Company Profile and etc.)

    • Table Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US